Business · Companies · 9 hrs ago
Oryzon seeks shareholder approval for a capital increase of up to €125 million
Oryzon Genomics plans to seek approval for a capital increase of up to €125 million at an extraordinary shareholders’ meeting scheduled for December 15.
The Spanish biotechnology company says the funds could strengthen its finances and support work on therapies for cancer and central nervous system diseases.
The proposed issue would exclude existing shareholders’ preferential rights to buy new shares, and the board would set the timing and price.
The minimum issue price would be €2 per share, according to the board’s proposal.
Oryzon shareholders approved a similar increase of up to €125 million in late 2025, and the company raised €30 million through this mechanism in April 2025.
Oryzon shares fell 8.93% on Friday to €2.35, and are down about 27% this year.
Shareholders will decide at the December 15 meeting whether to authorize the new increase.
Oryzon Genomics plans to ask shareholders to approve a capital increase of up to €125 million at an extraordinary meeting on 15 December.
The proposed issue would exclude existing shareholders’ pre-emption rights, and the board would set its timing, price and other terms.
The minimum price would be €2 per share, with the issue aimed mainly at qualified investors.
Oryzon says the funds could strengthen its balance sheet and support development of therapies for cancer and central nervous system diseases.
The company’s shares fell about 9% on Friday after the proposal was announced.
- Who
- Oryzon Genomics and its shareholders.
- What
- The company plans to seek approval for a capital increase of up to €125 million, excluding existing shareholders’ pre-emption rights.
- When
- The extraordinary shareholder meeting is scheduled for 15 December 2026.
- Where
- Not stated.
- Why
- Oryzon says the funds could strengthen its balance sheet and support development of new therapies.
This story does not have two clearly opposing sides.
Oryzon announced the proposed capital increase, and its shares fell about 9%.
Oryzon is scheduled to hold an extraordinary shareholder meeting to seek approval for the proposal.
- Maximum capital increase
- €125 million
- Shareholder meeting
- 15 December 2026
- Minimum share price
- €2
- Proposed maximum new shares
- 62.5 million
- Minimum investment for non-qualified investors
- €100,000 per investor in each individual offer